Mastectomy Clinical Trials

Clinical trials related to Mastectomy Procedure

SuperHERO: A Phase II Trial Evaluating Radiotherapy Omission for Low-risk HER2-positive Breast Cancer

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to find out whether it is safe to skip (omit) radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Please contact the study PI for exceptions, or if uncertainties arise.

• The trial is open to female and male patients who have undergone breast conserving surgery and have received neoadjuvant\* or adjuvant systemic therapy with a HER2-targeted therapeutic regimen.

• The maximum window between surgery (neoadjuvant cohort) or last chemotherapy (adjuvant cohort) and enrollment is 90 days.

• While the standard duration of neoadjuvant or adjuvant systemic therapy is at least 12 weeks, patients will be eligible if they receive a minimum of 8 weeks of systemic therapy. Patients treated with an antibody-drug conjugate (ADC; eg. T-DM1 or T-DXd) must have received at least 6 cycles of this treatment.

• \*For the neoadjuvant cohort: Patients are eligible if they achieved pCR with HER2-targeted preoperative treatment. Pathologic complete response is defined as ypT0/TisN0 based on surgical pathology. Patients treated with and ADC must have received at least 6 cycles of this treatment.

• The patient must be ≥18 years of age.

• The patient must have an ECOG performance status of 0, 1, or 2/Karnofsky performance status above 60.

• Histologically or cytologically confirmed invasive breast carcinoma.

• The tumor must have been determined to be HER2-positive by current ASCO/CAP guidelines based on local testing results.

• The tumor must have ER and PgR status assessed.

• The following staging criteria must be met according to AJCC 8th edition criteria:

⁃ Adjuvant cohort

• Following resection, the patient's primary tumor must be ≤ 3 cm.

• Surgical axillary evaluation via sentinel node biopsy or axillary dissection

• Surgical lumpectomy margins must be negative for invasive cancer and ductal carcinoma in situ (no ink on tumor).

⁃ Neoadjuvant cohort:

• Prior to neoadjuvant therapy, the patient's primary tumor must be \<5 cm by imaging studies with negative axillary nodes (cN0) based on axillary U/S, CT, PET or MRI. Physical examination alone is not sufficient documentation of cN0 status.

• The patient must have undergone surgical axillary nodal evaluation demonstrating ypN0 (eg. axillary node dissection, sentinel node biopsy with at least 3 sentinel lymph nodes removed, or sentinel node biopsy followed by axillary node dissection).

• Must be ypT0/TisN0 at surgery (lumpectomy); patients with residual non invasive disease (DCIS) in the surgical specimen (ypTis), are only eligible if residual DCIS spans ≤1 cm, and surgical margins are negative for DCIS.

• Bilateral mammogram or MRI within 52 weeks prior to enrollment.

Locations
United States
New Jersey
Memorial Sloan Kettering at Basking Ridge (All protocol activities)
RECRUITING
Basking Ridge
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING
Middletown
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING
Montvale
New York
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )
RECRUITING
Commack
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING
Harrison
Memorial Sloan Kettering Cancer Center (All protocol activites)
RECRUITING
New York
Memorial Sloan Kettering Nassau (All protocol activities)
RECRUITING
Rockville Centre
Contact Information
Primary
Lior Braunstein, MD
braunstl@mskcc.org
201-775-7446
Backup
Diana Roth O'Brien, MD
rothensd@mskcc.org
201-775-7605
Time Frame
Start Date: 2026-10-16
Estimated Completion Date: 2031-10-16
Participants
Target number of participants: 136
Treatments
Experimental: HER2-positive Breast Cancer
Participants have HER2-positive Breast Cancer
Related Therapeutic Areas
Sponsors
Leads: Memorial Sloan Kettering Cancer Center

This content was sourced from clinicaltrials.gov